IRVINE, CA, and HERSTAL, BELGIUM07.00 CET, 26 November 2018 – MDxHealth SA (Euronext: MDXH.BR) today announces that the New York State Department of Health has approved its SelectMDx test for Prostate Cancer. This completes MDxHealth’s state licensing requirements for SelectMDx, allowing the Company to offer the liquid biopsy test in all 50 states across the US.

SelectMDx is a proprietary, non-invasive urine-based molecular diagnostic test to identify men at increased risk of harboring aggressive prostate cancer, who may benefit most from earlier detection. Studies have shown that the test can reduce the need for unnecessary invasive biopsies and MRI procedures by up to 50%. A prospective clincal utility study recently published in the journal Urology Practice clearly demonstrated the value of SelectMDx in guiding urologists with their initial prostate biopsy decision-making. Similarly, a US based study published in the Journal of Urology assessing the cost-effectiveness of SelectMDx projected potential annual healthcare cost savings of over $500 million.  

“We’re thrilled to receive this approval from New York State which means SelectMDx will now be widely available to all physicians and their patients throughout the United States,” said Dr. Jan Groen, MDxHealth’s CEO. “This is a major milestone for our SelectMDx reimbursement and commercial strategy. It will support the growth of our test volumes for SelectMDx in the US, an important market, as well as in other territories.”

The New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP) regulates and oversees clinical diagnostic laboratories that test specimens from New York State residents, including Laboratory Developed Tests (LDTs). The CLEP seeks to ensure the accuracy and reliability of test results in clinical laboratories located in, or accepting specimens from, New York State residents. It is widely regarded as one of the most rigorous review processes due to its stringent quality standards.

The MDxHealth laboratory has been accredited by the College of American Pathologists (CAP) since 2012, and the Centers for Medicare and Medicaid Services (CLIA) since 2011. In addition, the laboratory is licensed by the California Department of Public Health, Pennsylvania State Department of Health, State of Rhode Island Department of Health and Maryland Department of Health.

About SelectMDx® for Prostate Cancer

SelectMDx for Prostate Cancer is a proprietary, urine-based molecular diagnostic test that offers a non-invasive ‘liquid biopsy’ method to assess a man’s risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby improving quality of life and lowering healthcare costs per patient. SelectMDx is available in the US and all EU member states. Since the introduction of the SelectMDx test in mid-2016, over 23,000 patients have been tested and 15 commercial contracts have been signed with US based insurance companies. The test has been included in the 2018 European Association of Urology (EAU) clinical guidelines.

About MDxHealth®

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit and follow us on social media at:, and

For more information:



Dr. Jan Groen, CEO

US: +1 949 812 6979

BE: +32 4 257 70 21

LifeSpring LifeSciences Communication

Leon Melens

NL: +31 6 538 16 427
Consilium Strategic Communications
David Daley, Chris Welsh, Jonathan Birt
UK: +44 20 3709 5701




This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.